FMA Advisory’s iShares Biotechnology ETF IBB Stock Holding History

FMA Advisory’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,929	Closed	-$591K	–	144
2021 Q1	$591K	Buy	3,929 +1,347	+52%	+$214K	0.18%	128
2020 Q4	$391K	Buy	2,582 +351	+16%	+$50.2K	0.13%	141
2020 Q3	$302K	Buy	+2,231	New	+$303K	0.12%	147

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FMA Advisory's IBB Position: Q2 2021 in Review

FMA Advisory sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 3,929 shares — an estimated $591K sold.

FMA Advisory first reported a position in IBB in Q3 2020 and held it in 3 quarters. The position peaked at $591K in Q1 2021. 863 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

FMA Advisory reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
FMA Advisory sold 3,929 iShares Biotechnology ETF shares in Q2 2021, an estimated $591K.
FMA Advisory first reported a position in iShares Biotechnology ETF in Q3 2020 and held it in 3 quarters.
FMA Advisory's iShares Biotechnology ETF position peaked at $591K in Q1 2021.
863 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on FMA Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.